Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Vellenga, Edo and van Putten, Wim and Ossenkoppele, Gert J. and Verdonck, Leo F. and Theobald, Matthias and Cornelissen, Jan J. and Huijgens, Peter C. and Maertens, Johan and Gratwohl, Alois and Schaafsma, Ron and Schanz, Urs and Graux, Carlos and Schouten, Harry C. and Ferrant, Augustin and Bargetzi, Mario and Fey, Martin F. and Löwenberg, Bob and Dutch-Belgian Hemato-Oncology Cooperative Group, . (2011) Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood, Vol. 118, H. 23. pp. 6037-6042.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006504

Downloads: Statistics Overview


We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemotherapy with etoposide and mitoxantrone or ASCT ater high-dose cyclophosphamide and busulfan. Of patients randomized (chemotherapy, n = 259; ASCT, n = 258), more than 90% received their assigned treatment. The 2 groups were comparable with regard to prognostic factors. The ASCT group showed a markedly reduced relapse rate (58% vs 70%, P = .02) and better relapse-free survival at 5 years (38% vs 29%, P = .065, hazard ratio = 0.82; 95% confidence interval, 0.66-1.1) with nonrelapse mortality of 4% versus 1% in the chemotherapy arm (P = .02). Overall survival was similar (44% vs 41% at 5 years, P = .86) because of more opportunities for salvage with second-line chemotherapy and stem cell transplantation in patients relapsing on the chemotherapy arm. This large study shows a relapse advantage for ASCT as postremission therapy but similar survival because more relapsing patients on the chemotherapy arm were salvaged with a late transplantation for relapse. This trial is registered at www.trialregister.nl as #NTR230 and #NTR291.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Hämatologie
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Hämatologie
UniBasel Contributors:Bargetzi, Mario J.
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:American Society of Hematology
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:16 Aug 2013 07:34
Deposited On:16 Aug 2013 07:32

Repository Staff Only: item control page